Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thrombo-embolism in the extended follow-up of the PROLONG study

Thrombosis and Haemostasis

Volumn 103, Issue 6, 2010, Pages 1152-1160

  Cosmi, Benilde ^a   Legnani, Cristina ^a   Tosetto, Alberto ^b   Pengo, Vittorio ^c   Ghirarduzzi, Angelo ^d   Testa, Sophie ^e   Prisco, Domenico ^f   Poli, Daniela ^f   Tripodi, Armando ^g   Palareti, Gualtiero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d Department of Internal Medicine I Angiology Arcispedale Santa Maria Nuova ^*  (Italy)

^e GENERAL HOSPITAL   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Atherosclerosis; Hypercoagulability; Oral anti coagulants; Risk factors; Venous thromboembolism

Indexed keywords

D DIMER; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; ADOLESCENT; CONTROLLED STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOLOGICAL MARKERS; COMORBIDITY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77953170321     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-11-0759     Document Type: Article

References (36)

1. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
2. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907. (Pubitemid 29141050)
3. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169.
4. Kearon C, Kahn S R, Agnelli G, et al. Antithrombotic Therapy for Venous Thromboembolic Disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 2008; 133:454S-545S.
5. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. Arch Intern Med 2000; 160: 761-768. (Pubitemid 30165236)
6. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
7. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639. (Pubitemid 36975995)
8. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12. (Pubitemid 34092568)
9. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318.
10. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. J Am Med Assoc 2003; 290: 1071-1074. (Pubitemid 37430448)
11. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789. Erratum in: N Engl J Med 2006; 355: 2797.
12. Cosmi B, Legnani C, Tosetto A, et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis 2009; 28: 381-388.
13. Becattini C, Agnelli G, Prandoni P, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83.
14. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189. (Pubitemid 34522408)
15. Prandoni P, Ghirarduzzi A, Prins MH et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4: 1891-1896. (Pubitemid 44226764)
16. Luxembourg B, Schmitt J, Humpich M, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102: 668-675.
17. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56-61.
18. Folsom AR, Lutsey PL, Astor BC, et al. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-619.
19. Matta F, Singala R, Yaekoub AY, et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
20. Prandoni P, Cogo A, Bernardi E, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88: 1730-1735. (Pubitemid 23296919)
21. Cini M, Legnani C, Cavallaroni K, et al. A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. J Thromb Haemost 2003; 1: 2681-2683.
22. Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002; 108: 263-271.
23. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336. (Pubitemid 36237283)
24. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
25. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
26. Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349: 1247-1256.
27. Kearon C. Diagnosis of pulmonary embolism. Can Med Assoc J 2003; 168: 183-194.
28. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
29. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
30. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism - a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-380.
31. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004; 18: 477-482.
32. Doggen CJ, Lemaitre RN, Smith NL, et al. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004; 2: 700-701.
33. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 2002; 53: 101-105.
34. Kaba NK, Francis CW, Moss AJ, et al. Effects of lipids and lipid-lowerinf therapy on haemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004; 2: 718-725.
35. Van de Ree MA, De Maat MPM, Kluft C, et al. Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. J Thromb Haemost 2003; 1: 1753-1757.
36. Legnani C, Palareti G, Cosmi B, et al. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica 2008; 93: 900-907.